Enovis Q2 2026 earnings: Reconstructive growth lifts margins
Enovis (NYSE: ENOV) reported Q2 2026 net sales of $582.8 million, up 3.2% from $564.5 million a year earlier, while GAAP diluted EPS improved to a loss of $0.02 from a loss of $0.64. Adjusted EPS rose to $0.90 from $0.72, and adjusted EBITDA margin expanded to 17.9% from 16.2%. Reconstructive was the main sales driver, while higher gross margin moved the company back to GAAP operating profit.
Core earnings data
For the quarter ended July 3, 2026, Enovis posted 4.8% organic sales growth, exceeding its reported growth rate. More importantly, gross profit and adjusted EBITDA increased faster than revenue, indicating better operating leverage during the quarter.
The GAAP net loss narrowed substantially, although adjusted earnings remained well above the reported result. Major adjustments included acquired-intangible amortization, restructuring charges, stock-based compensation and strategic transaction costs.
| Metric | Q2 2026 | Q2 2025 | Year-over-year change |
|---|---|---|---|
| Net sales | $582.8 million | $564.5 million | +3.2% |
| GAAP gross profit | $359.2 million | $334.7 million | Approximately +7.3%; margin rose to 61.6% from 59.3% |
| GAAP operating income (loss) | $17.4 million | $(16.8) million | $34.2 million improvement |
| GAAP net loss | $(1.0) million | $(36.5) million | Loss narrowed by $35.5 million |
| GAAP diluted EPS | $(0.02) | $(0.64) | $0.62 improvement |
| Adjusted net income from continuing operations | $52.2 million | $41.3 million | Approximately +26.4% |
| Adjusted diluted EPS | $0.90 | $0.72 | +25.0% |
| Adjusted EBITDA | $104.3 million | $91.2 million | Approximately +14.4%; margin rose to 17.9% from 16.2% |
Enovis revised its prior-period non-GAAP figures under definitions that no longer adjust for inventory step-up charges. The Q2 2025 comparisons above reflect those revised figures.
Business and segment performance
Reconstructive generated the majority of the company’s reported revenue increase. Prevention & Recovery, or P&R, declined slightly on a reported basis but remained positive organically because divestitures reduced reported sales.
| Business | Q2 2026 sales | Q2 2025 sales | Reported growth | Organic growth |
|---|---|---|---|---|
| U.S. Bracing & Support | $127.6 million | $120.9 million | +5.6% | +5.6% |
| U.S. Other P&R | $59.6 million | $70.8 million | -15.8% | +4.6% |
| International P&R | $101.0 million | $98.9 million | +2.1% | 0.0% |
| Total Prevention & Recovery | $288.2 million | $290.6 million | -0.8% | +3.5% |
| U.S. Reconstructive | $137.8 million | $129.5 million | +6.4% | +6.4% |
| International Reconstructive | $156.7 million | $144.5 million | +8.5% | +6.2% |
| Total Reconstructive | $294.5 million | $274.0 million | +7.5% | +6.3% |
The P&R segment’s existing businesses added $10.1 million of sales, but divestitures reduced revenue by $14.4 million. Currency translation added $2.1 million. Across Enovis as a whole, existing businesses contributed $27.3 million of growth and currency added $5.4 million, partially offset by the divestiture impact.
Gross margin expansion drove the profit recovery
The central earnings development was the expansion in gross margin. Cost of sales fell by approximately $6.3 million even as net sales increased by $18.2 million, lifting GAAP gross margin by 230 basis points to 61.6%.
Below the gross profit line, selling, general and administrative expense declined by approximately $3.3 million. Enovis also had no purchase-of-royalty-interest expense, compared with $10.0 million in the prior-year quarter. These benefits more than offset restructuring charges rising to $4.9 million from $0.7 million and research and development expense increasing to $31.7 million from $30.7 million.
As a result, Enovis swung from a GAAP operating loss to operating income. Interest expense of $8.0 million, other expense of $1.9 million and income tax expense of $8.5 million kept the company slightly loss-making at the GAAP net income level.
Cash flow and balance sheet
The cash flow figures disclosed in the release cover the first six months of 2026 rather than Q2 alone. Six-month operating cash flow increased to $99.0 million from $46.2 million, supported by a much smaller net loss and less cash tied up in inventories and receivables than in the comparable period.
Purchases of property, plant, equipment and intangibles totaled $96.7 million, up from $87.6 million. Financing activities used $24.5 million, and cash declined by $23.8 million during the six-month period to $12.6 million.
Inventory increased to $601.7 million from $584.4 million at the end of 2025. Total current and long-term debt was approximately $1.285 billion, compared with approximately $1.297 billion at year-end.
Full-year 2026 guidance
Enovis reaffirmed every major component of its full-year outlook. The ranges were not reduced despite management’s expectation of a more dynamic macroeconomic environment in the second half.
| Metric | Latest FY2026 guidance | Status |
|---|---|---|
| Revenue | $2.31 billion to $2.37 billion | Reaffirmed |
| Organic revenue growth | 4% to 6% | Reaffirmed |
| Adjusted EBITDA | $425 million to $435 million | Reaffirmed |
| Adjusted diluted EPS | $3.52 to $3.73 | Reaffirmed |
| Free cash flow conversion | At least 25% | Reaffirmed |
The revenue and adjusted EBITDA ranges are based on current exchange rates. Free cash flow conversion is defined as free cash flow divided by adjusted net income.
Management view
CEO Damien McDonald said the results reflected a more focused organization and a portfolio reshaped over recent years. Management pointed to improving commercial execution and product innovation as competitive drivers, while acknowledging that Enovis still needs to establish more consistent, durable growth. The company also expects end markets and macroeconomic conditions to become more dynamic during the second half.
Recent insider transactions
The insider dataset contains an inconsistency: its six-month summary reports zero purchase transactions, but the detailed transaction log lists four June purchases by officer Oliver Engert. Those four entries have a combined stated transaction value of approximately $92,088 and are marked as direct ownership.
| Date | Insider | Transaction | Price per share | Stated value |
|---|---|---|---|---|
| June 15, 2026 | Oliver Engert, Officer | Purchase | $20.92 | $20,920 |
| June 11, 2026 | Oliver Engert, Officer | Purchase | $20.99-$21.75 | $25,948 |
| June 11, 2026 | Oliver Engert, Officer | Stock award | $20.99 | $25,188 |
| June 10, 2026 | Oliver Engert, Officer | Purchase | $23.00 | $23,000 |
| June 1, 2026 | Oliver Engert, Officer | Purchase | $22.22 | $22,220 |
| June 30, 2026 | Christine Ortiz, Director | Stock award | $0.00 | $0 |
Because of the conflict between the summary and detailed records, the underlying regulatory filings would provide the more reliable transaction record.
Risks investors should watch
- P&R reported revenue remains under pressure. The segment declined 0.8% even though organic growth was 3.5%, as divestitures created a $14.4 million quarterly revenue headwind.
- Margin improvement must prove durable. Q2 benefited from lower cost of sales, reduced SG&A expense and the absence of the prior-year royalty-interest purchase. Restructuring and acquisition-integration costs remain part of the GAAP-to-adjusted earnings gap.
- Cash conversion and balance-sheet demands remain important. Six-month operating cash flow improved, but investment spending absorbed most of it. Cash fell to $12.6 million while inventory increased and total debt remained approximately $1.285 billion.
- The outlook assumes current exchange rates amid a less predictable second half. Currency contributed $5.4 million to Q2 reported sales growth, while management warned of a more dynamic macroeconomic environment.
Summary
Enovis delivered modest reported revenue growth in Q2 2026, led by Reconstructive, but the more significant change was the recovery in margins and operating profit. The company maintained its full-year guidance, indicating that the quarter did not require an outlook reset. Investors’ next focus areas are whether P&R can translate organic gains into reported growth, whether margin expansion continues and whether improved earnings produce the targeted cash conversion.
This article may include AI-generated content that is human-reviewed, which is for reference and general information purposes only and does not constitute investment advice.
Recommended Articles









Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.